Akero Therapeutics Inc (NASDAQ:AKRO)

49.29
Delayed Data
As of Jan 27
 0.00 / 0.00%
Today’s Change
7.52
Today|||52-Week Range
54.88
-10.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$2.2B

Company Description

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Contact Information

Akero Therapeutics, Inc.
601 Gateway Boulevard
South San Francisco California 94080-7006
P:(650) 487-6488
Investor Relations:

Employees

Shareholders

Other institutional53.06%
Mutual fund holders31.34%
Individual stakeholders31.00%

Top Executives

Andrew ChengPresident, Chief Executive Officer & Director
Jonathan YoungChief Operating Officer & Executive Vice President
William R. WhiteCFO, Treasurer, EVP & Head-Corporate Development
Timothy RolphChief Scientific Officer
Reshma ShringarpureVice President-Clinical Research & Medical Affairs